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Developmental signalling pathways are implicated in the formation and maintenance of the adrenal
gland, but their roles are currently not well deﬁned. In recent years it has emerged that Sonic hedgehog
(Shh) and Wnt/b catenin signalling are crucial for the growth and development of the adrenal cortex.
Here we demonstrate that Fibroblast growth factor receptor (Fgfr) 2 isoforms IIIb and IIIc are expressed
mainly in the adrenal subcapsule during embryogenesis and that speciﬁc deletion of the Fgfr2 IIIb iso-
form impairs adrenal development, causing reduced adrenal growth and impaired expression of SF1
and steroidogenic enzymes. The hypoplastic adrenals also have thicker, disorganised capsules which
retain Gli1 expression but no longer express Dlk1. Fgfr2 ligands were detected in both the capsule and
the cortex, suggesting the importance of signalling between the capsule and the cortex in adrenal
development.
 2013 Elsevier Ireland Ltd. Open access under CC BY license.1. Introduction adrenal from e12.5 throughout life (King et al., 2009; Ching andThe adrenal cortex is the primary site of steroid
synthesis, producing glucocorticoids under the control of the
hypothalamic–pituitary–adrenal (HPA) axis and mineralocortic-
oids under the control of the renin-angiotensin system (RAS).
Adrenocortical development originates in a group of cells lying
between the urogenital ridge and the dorsal aorta, forming the
precursors of the adrenal glands and the gonads, the adrenogo-
nadal primordium (AGP) (Hatano et al., 1996). At around embry-
onic day e9.0 in the mouse these cells begin to express the
steroidogenic transcription factor Steroidogenic Factor-1 (SF1),
which is essential for both adrenal and gonadal development
(Luo et al., 1994). By e12.0, cells of the dorsal medial AGP form
the adrenocortical primordium which is invaded by migrating
sympathetic neural crest cells that form the central adrenal me-
dulla (Hatano et al., 1996). The gland is also encapsulated at this
time in a poorly understood manner. Zonation occurs around
birth (for reviews see (Kim et al., 2009; Laufer et al., 2012). Over
the last few years signalling pathways involved in adrenal devel-
opment have begun to be elucidated. We and others have shown
that sonic hedgehog (Shh) is expressed in relatively undifferenti-
ated steroidogenic cells in the subcapsular region of the mousest growth factor receptor.
ocrinology, William Harvey
Mary University of London,
el.: +44 (0)20 78826237;
der CC BY license.Vilain, 2009; Huang et al., 2010). The Shh signal is transduced
by capsule cells, some of which delaminate into the cortex, lose
their responsiveness to Shh, and become steroidogenic (King
et al., 2009; Laufer et al., 2012). Deletion of Shh from steroido-
genic tissues causes adrenal hypoplasia, and interestingly the
adrenal capsule is markedly thinner. Similar targeted deletion of
b catenin, which like Shh is expressed just underneath the capsule
in the murine adrenal cortex from e12.5, also causes adrenal
hypoplasia, demonstrating that canonical Wnt signalling is critical
for adrenal development.
Like Shh and Wnts, the pathways activated by the binding of
Fibroblast Growth Factors (FGFs) to their receptors are of crucial
importance for many developmental processes as well as in disease
(Ornitz and Itoh, 2001; Turner and Grose, 2010). Four signalling
FGF receptors, FGFR1-4, have been identiﬁed; these are transmem-
brane tyrosine kinases which contain three extracellular immuno-
globulin (Ig) domains. FGFRs 1–3 are alternatively spliced in the
third Ig domain such that an invariant exon IIIa is spliced to either
exon IIIb or IIIc to produce IIIb or IIIc isoforms. Embryos with a glo-
bal Fgfr2 IIIb deletion have hypoplastic adrenals (Revest et al.,
2001), and deletion of both isoforms of FGFR2 from steroidogenic
tissue recapitulates this phenotype (Kim et al., 2007), implying that
the receptor is both expressed in the adrenal cortex and necessary
for development. However, neither the expression pattern of
FGFR2 isoforms, nor the adrenal phenotypes of the knockouts,
has been investigated further.
Here we demonstrate that Fgfr2 IIIb and IIIc isoforms are ex-
pressed underneath the embryonic adrenal capsule, in a similar
expression pattern to Shh and b catenin. Fgfr2 IIIb null mouse
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differentiation, and a larger and less deﬁned capsule. However,
the expression of the Shh target gene Gli1 in capsular cells per-
sisted in Fgfr2 IIIb null adrenals. Instead, the capsular expression
of Dlk1 (also known as Pref-1), a member of the Notch family of
EGF repeat-containing proteins (for review see (Sul, 2009)), was
strongly and speciﬁcally reduced in the Fgfr2 IIIb knock-out. Final-
ly, we performed RT-PCR analysis of FGFs in laser capture dissected
mouse embryonic adrenal tissues, and detected Fgf1 in the adrenal
capsule and Fgf2 and Fgf9 in the adrenal cortex.2. Methods
2.1. Mice
Mice were housed in rooms with controlled light and tempera-
ture and treated under the Home Ofﬁce Animals (Scientiﬁc Proce-
dures) Act 1986.
We used Cre-Lox transgenics to generate Fgfr2 IIIb null embryos,
taking advantage of a K5cre construct which, in female mice, is mis-
expressed in the oocyte in addition to basal keratinocytes, resulting
in global deletion of Fgfr2 IIIb (Grose et al., 2007; Ramirez et al.,
2004). Brieﬂy, Fgfr2 IIIb ﬂox/ﬂox male mice were crossed with female
keratin K5cre/+; Fgfr2 IIIb ﬂox/+ mice. Wild type and K5cre/+ females
were sacriﬁced by CO2 asphyxiation at day 15.5 post-fertilisation
and embryos were snap frozen in liquid nitrogen and stored at
80 C. Sagittal sections were obtained on a freezing-microtome
(Leica GM 1510 S or Leica 3050 S) at 12 lm thickness, and
mounted on Superfrost Plus slides (VWR). Sections were stained
with hematoxylin and eosin using standard procedures.
2.2. Non-radioactive in situ hybridization (NR-ISH)
RNA was extracted from adult adrenal tissues using an RNeasy
Mini kit (Qiagen), and cDNA was prepared from random-primed
total RNA using Maloney Murine Leukemia Virus-Reverse Trans-
criptase (MMLV-RT, Promega). Fgfr2, Fgfr2 IIIb, Fgfr2 IIIc and
Dlk1 cDNAs were ampliﬁed (PCR primer sequences are listed in
Supplemental) and cloned into pGEM T-easy vectors (Promega).
The vectors were sequenced and linearised with the appropriate
restriction enzymes. The mouse Gli1 probe (King et al., 2009) and
Sf1 probe (Guasti et al., 2011) have been described previously.
Digoxigenin (DIG)-labelled cRNA probes synthesis and NR-ISH
was performed as described (Guasti et al., 2011).
2.3. Immunostaining
Immunostaining of sections and image acquisition and process-
ing was performed according to (Guasti et al., 2011). Anti-Cyp11b1
(1:20 dilution), anti-P450 Side Chain Cleavage (Scc, 1:1000 dilu-
tion, Millipore AB1244), anti-PCNA (F2, sc25280, Santa Cruz Bio-
technology, 1:1000 dilution) and anti-Cleaved caspase 3 (Cell
Signaling, D175, 1:500 dilution) were used in this study. For immu-
nohistochemical comparative analysis (as well as for Gli1, Sf1 and
Dlk1 NR-ISH), all steps from ﬁxation and sectioning to staining
and image acquisition were performed in parallel in wild-type
and knock-out mice.
2.4. Laser capture microdissection
Sections of e15.5 mouse embryos were cut at 12 lm thickness
and mounted onto polyethylene napthalate-membrane slides (Life
Technologies). Sections were ﬁxed and stained with cresyl violet
using the LCM staining kit (Ambion) according to the manufac-
turer’s instructions. Sections were allowed to dry at roomtemperature for 5 min and immediately used for laser capture
microdissection using a PALM MicroBeam (Zeiss). Adrenal capsule,
adrenal cortex and pooled tissues (brain, liver, heart, skin, gut, and
lungs) were collected in RLT lysis buffer (RNeasy kit, Qiagen) and
RNA was extracted according to the manufacturer’s instructions.
cDNAwas synthesised using a Sensiscript RT kit (Qiagen) according
to the manufacturer’s instructions.3. Results
3.1. Expression pattern of FGFR2 isoforms
We investigated the expression of Fgfr2 isoforms IIIb and IIIc in
e15.5 wild type (WT) mouse adrenals by non-radioactive in situ
hybridization (NR-ISH) using isoform-speciﬁc probes (Fig. 1A–F):
both IIIb and IIIc isoforms were expressed underneath the capsule
in cells that do not express Cyp11b1. This is the same expression
pattern we observed for Shh in developing and adult mouse (King
et al., 2009) and rat (Guasti et al., 2011) adrenals. A probe recogn-
ising both isoforms gave similar results; however, upon longer
exposure, some capsular Fgfr2 expression could be detected with
this probe (Fig. S1).
3.2. Fgfr2 IIIb null embryos have hypoplastic adrenals
As Fgfr2 IIIb null embryos die at birth, we analysed e15.5 em-
bryos. The adrenals in the null embryos are clearly smaller and have
a markedly thicker capsule containing rounded rather than the typ-
ically elongated cells (Fig. 1G–L), and a less well-deﬁned boundary
with the cortex (arrows in Fig. 1L). The expression of Fgfr2 IIIc did
not seem to be affected by IIIb deletion (Fig. S1). To investigate the
mechanisms for the hypolasticity of the gland we studied markers
of apoptosis and proliferation. While apoptotic cells (detected with
an anti-cleaved caspase 3 antibody) were rare and mainly localised
in the medulla in both WT and knock-out (KO) adrenals (Fig. S2),
analysis of cell proliferation with an anti-PCNA antibody showed
that, whereas the number of PCNA-positive cortical cells immedi-
ately adjacent to the capsule did not differ between WT and KO
mice, PCNA positive nuclei were clearly present in the capsule of
the KO, but absent in the WT, and there were fewer proliferative
cells in the inner cortex of the KO adrenal compared toWT adrenals.
3.3. Fgfr2 IIIb null adrenals have reduced steroidogenic enzyme
expression
Next, the expression of the pan-steroidogenic marker Cyp11a1
(Scc) and the ZF marker Cyp11b1 was compared between WT
and knockout (KO) adrenals using speciﬁc antibodies (Fig. 2). The
expression of both enzymes was noticeably reduced in KO em-
bryos, with fewer cells expressing the enzymes and at a lower le-
vel. NR-ISH analysis also showed that Sf1 mRNA expression was
reduced in KO adrenals (Fig. 2I and J).
3.4. Analysis of gene expression in the capsule of Fgfr2 IIIb null
adrenals
As signalling through Fgfr2 IIIb is required to establish Shh
expression in the developing limb bud (Revest et al., 2001), it
was therefore possible that the defects in adrenal development de-
scribed above are a consequence of perturbed Shh signalling. Shh
activity at the capsule was assessed by Gli1 NR-ISH (Fig. 3). Gli1
expression was readily detected in the Fgfr2 IIIb KO adrenal cap-
sule, and was apparently expressed at higher levels than in the
wild type mouse, with more clusters of Gli1 positive cells observed.
To investigate the capsule phenotype further, we also studied the
Fig. 1. (A–F) NR-ISH analysis of e15.5 mouse adrenal glands using Fgfr2 IIIb (B and C) and IIIc (E and F) speciﬁc probes combined with Cyp11b1 immunolocalization. Fgfr2
positive cells are labelled red, Cyp11b1 cells are labelled green and cell nuclei are labelled blue (Cap. = capsule, Med. = medulla). (G-L) Hematoxylin and eosin staining of
wild-type (+/+, G–I) and fgfr2 IIIb knock out (-/-, J–L) adrenals. (M, N) Immunohistochemical analysis of PCNA expression in wild-type (+/+, M) and fgfr2 IIIb knock-out
(-/-, N) adrenals. Arrows in N point to PCNA-positive cells in the adrenal capsule. Scale bars = F, 50 lm (applies to A–F); J, 150 lm (applies to G and J); L, 50 lm (applies to H, I,
K, and L); M and N = 100 lm. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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(Beuschlein et al., 2002), which is also expressed in the medulla.
Interestingly, Dlk1 expression was completely lost from theadrenal capsule but retained in the medulla, which is comparable
in size to that of the wild type adrenal, indicating that medulla for-
mation is unaffected.
Fig. 2. Expression of Scc (A–D), Cyp11b1 (E–H) and Sf1 in e15.5 WT (A, B, E, F, and I) and Fgfr2 IIIb KO (C, D, G, H, and J) adrenals. Scale bar = 200 lm (A, C, E, and G); 50 lm (B,
D, F, H, I, and J). Med. = medulla, Cx. = cortex.
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Finally, we performed laser capture microdissection on e15.5
WT mouse adrenal tissues, collecting tissues from both the capsuleand the cortex. RT-PCR performed on RNA isolated from these tis-
sues, using primers against FGF isoforms, detected expression of
Fgf1, in the cortex, and Fgf 2 and 9, in the capsule (Fig. 4). The detec-
tion of Shh expression in the cortical fraction and the preferential
Fig. 3. NR-ISH of WT (+/+) and Fgfr2 IIIb KO (-/-) e15.5 mouse adrenals using Gli1 (A and B) and Dlk1 (C–F) riboprobes. Arrows in A and B indicate clusters of Gli1 positive cells in
the capsule. Capsule cells in A, B, E and F are between the brackets. Scale bars = 100 lm. Med. = medulla.
Fig. 4. RT-PCR analysis of Fgfs and Fgfrs expression in laser capture microdissected
e15.5 adrenal capsule and cortex. Control cDNA was made from pooled tissues
including lung, heart, liver, bone and gut.
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indicated the accuracy of the microdissection. Both Fgfr2 IIIb, albeit
at lower levels than in the cortex, and IIIc, were ampliﬁed in the
capsule, in keeping with the NR-ISH experiments (see Fig. 1 and
Fig. S1).
4. Discussion
Germline knockout of the IIIb exon of the Fgfr2 gene results in
mice that die at birth from multiple developmental defects,
identifying Fgfr2 IIIb as a critical mediator of organogenesis (DeMoerlooze et al., 2000; Revest et al., 2001). We have shown here
that adrenal development is also affected, with a detectable but
smaller gland at e15.5 in which expression of the steroidogenic
markers Sf1, Scc and Cyp11b1 is reduced, compared to a wild type
adrenal. Analysis of apoptosis and proliferation markers demon-
strates that the hypoplasia is likely a consequence of a reduction
of inner cortical cell proliferation. In Shh null adrenals, apoptosis
and proliferation indices are largely normal in the cortex and the
defect in growth is believed to be a consequence of the very thin
capsule, from which mesenchymal cells differentiate to populate
the steroidogenic cortex in the wild type organ. b catenin KO,
however, does result in reduced cortical proliferation.
Fgf and Shh pathways interact in several developmental set-
tings including the limb bud (Laufer et al., 1994), the cerebellum
(Fogarty et al., 2007) and the lung (Chuang et al., 2003), and Shh
has been shown to be under both positive and negative regulation
by FGFs. In the developing limb, for example, Fgf10 signalling to
the apical ectodermal ridge through Fgfr2 IIIb is required to initiate
Shh expression in the zone of polarising activity in the posterior
limb bud and thus establish the anterior–posterior limb axis
(Revest et al., 2001), and expression of Shh is restricted to the pos-
terior limb bud by inhibitory Fgf signalling in the anterior limb to
control limb patterning (Mao et al., 2009; Zhang et al., 2009). The
maintained expression of the Shh target gene Gli1 that we observe
in the adrenal capsule demonstrates that FGF signalling through
Fgfr2 IIIb is not required for Shh signalling in this setting, and
may act to restrict it, given the apparent increased Gli1 expression
in the Fgfr2 IIIb KO adrenal capsule. Fgf and Wnt/b catenin
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developing skin (Reddy et al., 2001), mammary tissue (Veltmaat
et al., 2006) and liver (Berg et al., 2007; Mavila et al., 2012), and
Fgfs 1, 4 and 8 activating b catenin signalling in murine embryonic
liver (Sekhon et al., 2004). We have not examined b catenin expres-
sion in the null adrenal but note that the phenotypes of the Fgfr2
IIIb and b catenin KO adrenals are similar, with impaired develop-
ment, reduced expression of steroidogenic markers and reduced
cortical cell proliferation evident (Kim et al., 2008). However, it
does not appear that b catenin KO causes a capsule phenotype as
we see here, so we do not expect that this aspect of the phenotype
is a consequence of impaired Wnt signalling.
The two receptor isoforms are apparently predominantly ex-
pressed in the same cells in the cortex, although expression was
detected in the adrenal capsule at lower levels. As the adrenal
gland is present, signalling through Fgfr2 IIIb is not necessary for
the formation of the adrenal primordium but, like Shh and b cate-
nin (Kim et al., 2008), this receptor is required for the subsequent
growth of the gland. The Fgfr2 IIIb KO examined here is a global
knockout and it is therefore possible that the observed effects on
adrenal development may be secondary to those on other organ
systems, although no effect on the gonads was observed, indicating
that the adrenal hypoplasia was not secondary to effects on the
adrenogonadal primordium (Revest et al., 2001). Conditional dele-
tion of both isoforms of Fgfr2 from steroidogenic tissue also leads
to adrenal hypoplasia (Kim et al., 2007) and global hemizygous
deletion of exon IIIc of Fgfr2 does not appear to have any gross ef-
fect on adrenal development, unlike on the development of other
visceral organs (Hajihosseini et al., 2001). Taken together, these
observations suggest that the effect of loss of Fgfr2 IIIb on the adre-
nal is direct, although formal proof would require the generation of
adrenal speciﬁc knockouts.
Fgfr2 IIIb is activated by ﬁve known ligands, Fgfs 1, 3, 7, 10 and
22 (Zhang et al., 2006), but of these we could only detect Fgf1,
which is expressed in the cortex. Fgfr2 IIIc is also expressed in
the adrenal cortex, and Fgfs 2 and 9 (Lavine et al., 2005) activate
this isoform, both being detected in the capsule. Fgf2 acts as a
mitogen for adrenocortical cells in culture and in regeneration
experiments (Crickard et al., 1981; Lepique et al., 2004; Chu
et al., 2009). However, the normal adrenal phenotype observed
on hemizygous Fgfr2 IIIc deletion suggests that signalling through
this receptor may not be necessary during development (Hajihos-
seini et al., 2001). Given the detection, albeit at low levels, of recep-
tor expression in the adrenal capsule, it is not possible to
determine whether Fgf1 is acting on the IIIb isoform receptor in
the cortex or in the capsule, or both. It will be interesting to deter-
mine the relative importance of signalling from the cortex to the
capsule (Fgf1/Fgfr2 IIIb), from the capsule to the cortex (Fgfs 2
and 9/Fgfr2 IIIc) or within the capsule (Fgfs 2 and 9/Fgfr2 IIIc) or
cortex (Fgf1/Fgfr2 IIIb), for adrenal growth and development.
The thicker and disorganised adrenal capsule phenotype we ob-
serve is similar to that seen in melanocortin 2 receptor (Mc2r, ACTH
receptor) KO adrenals (Chida et al., 2007), perhaps indicating an
interaction between the FGF and ACTH signalling pathways, and
this warrants further investigation. However, as both Mc2r and
Pomc (Karpac et al., 2005) KO adrenals are otherwise normal at
birth, we do not feel that impaired ACTH signalling is a likely
mechanism for the effects on the growth and differentiation of
the gland we see here. The observation that Dlk1 expression is spe-
ciﬁcally lost from the adrenal capsule in the null adrenals is fasci-
nating and suggests that this may be the cause of the capsule
phenotype. Enucleation experiments in rats, in which the inner
mass of the adrenal is removed and the cortex regenerates from
the capsule and adherent subcapsular cells, have demonstrated
that Dlk1 expression is immediately downregulated and not
re-established until the zonation of the cortex has been restored(Halder et al., 1998). This led to the suggestion that Dlk1 is a neg-
ative regulator of adrenal differentiation, analagous to its role in
adipogenesis (Smas and Sul, 1993). Unusually, however, the
expression pattern of Dlk1 differs between rats and mice, with it
being speciﬁcally expressed in subcapsular cells in the rat (Halder
et al., 1998), rather than in the capsule (Beuschlein et al., 2002),
perhaps making comparisons of the role of the protein in the two
species invalid. Nevertheless, it is possible that Dlk1 negatively
regulates differentiation of the Gli1-positive capsular stem cells
in a similar manner and its downregulation is in response to the
impaired recruitment of these cells into the cortex caused by the
Fgfr2 IIIb KO, perhaps as a consequence of the effects on the growth
and organisation of the capsule.
These data highlight the importance of FGF signalling in adrenal
development. Shh expression is not greatly perturbed by the loss of
FGF signalling, so presumably other, as yet unidentiﬁed, mecha-
nisms are involved in the control of adrenal development and
growth of the capsule by signalling through Fgfr2 IIIb. Determining
these mechanisms is an important goal for understanding adrenal
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